At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
Pazopanibdrug
Likely dose
Pazopanib 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Extension Study to Protocol MD7108240: Pazopanib Eye Drops in Subjects With Neovascular Age-related Macular Degeneration
In Brief
A Phase 2 clinical trial evaluating Pazopanib for Macular Degeneration. Completed, enrolled 42 participants across 17 sites in 3 countries.
Detailed Summary
This is a two month study to allow continued treatment with pazopanib eye drops. Study may be extended to 5 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Degeneration
CountriesAustralia, Italy, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedAug 2008
Primary CompletionSep 2009
TodayJul 2026
First PostedAug 13, 2008
Enrollment StartJun 25, 2008
Primary CompletionSep 9, 2009
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 17.9 years ago
Interventions
Pazopanibdrug
5 mg/ml TID, 2 mg/ml TID or 5 mg/ml QD